Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Clinical management of pancreatic cancer remains challenging. Here, the authors suggest SMARCD3 as a potential epigenetic dependency establishing the metabolic landscape in aggressive pancreatic cancer cells and as a potential therapeutic target in pancreatic cancer.

Bibliographic Details
Main Authors: L. Paige Ferguson, Jovylyn Gatchalian, Matthew L. McDermott, Mari Nakamura, Kendall Chambers, Nirakar Rajbhandari, Nikki K. Lytle, Sara Brin Rosenthal, Michael Hamilton, Sonia Albini, Martin Wartenberg, Inti Zlobec, José A. Galván, Eva Karamitopoulou, Vera Vavinskaya, Alexis Wascher, Andrew M. Lowy, Christian M. Schürch, Pier Lorenzo Puri, Benoit G. Bruneau, Diana C. Hargreaves, Tannishtha Reya
Format: Article
Language:English
Published: Nature Portfolio 2023-01-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-023-35796-7

Internet

https://doi.org/10.1038/s41467-023-35796-7

Similar Items